Company profile: Synthego
1.1 - Company Overview
Company description
- Provider of genome engineering platforms enabling access to CRISPR to accelerate life science R&D, leveraging machine learning, automation, and gene editing. Offers synthetic and synthesized sgRNA/gRNA for research and therapeutic development, GMP-grade and IND-enabling sgRNA for clinical trials and pre-IND studies, and the engineered hfCas12Max nuclease for higher on-target editing.
Products and services
- GMP sgRNA: GMP-grade sgRNAs are produced for use in clinical trials, complying with FDA and EMA regulations for CRISPR-based therapies
- HfCas12Max Nuclease: An engineered nuclease from Cas12i, designed for higher on-target editing and reduced off-target effects, used in CRISPR applications
- Synthetic sgRNA: Synthego offers synthetic single guide RNA for research use, providing flexibility in scale, length, and purity to suit specific experimental needs
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Synthego
Affinergy
HQ: United States
Website
- Description: Provider of application-specific coatings and medical devices for orthopedic and cardiovascular markets; diagnostic assays including an ApoL1 G0 variant blood test to inform kidney transplantation, therapeutic drug monitoring for Tacrolimus, Vancomycin and Hepcidin, and immune profile diagnostics for autoimmune diseases; plus peptide and antibody display services to identify interactions and binding affinities, and epitope mapping.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Affinergy company profile →
PrimeraDx
HQ: United States
Website
- Description: Provider of multiplexed infectious disease assays and Scalable Target Amplification Routine technology for simultaneous quantitative measurement of multiple nucleic acid targets. Offers the ICEPlex system combining PCR and capillary electrophoresis, companion diagnostics, a C. difficile assay, ViraQuant for virus quantification, translational medicine research solutions, and pharma quality control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PrimeraDx company profile →
Comecer
HQ: Italy
Website
- Description: Provider of protection technologies in nuclear medicine, isolation, and nuclear power plant equipment, and of screening systems for special applications serving hospitals, universities, industrial groups, and research organizations. Products include aseptic processing and containment systems, a Terbium-161 production line, the IRIS radiopharmaceutical injection system, THERABED protected admission management, ISP radioactive waste management, and dose calibrators.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Comecer company profile →
Polyganics
HQ: The Netherlands
Website
- Description: Provider of bioresorbable medical devices for natural tissue repair and regeneration, developing, manufacturing, and marketing products including LIQOSEAL dura sealant patch for watertight dural closure; dental and bone grafting materials such as GUIDOR easy-graft, MatrixDerm, MatrixOss Granules, and SynOss Putty; and dural repair solutions like DuraMatrix-Onlay Plus.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Polyganics company profile →
Advicenne
HQ: France
Website
- Description: Provider of specialty pharmaceutical treatments targeting rare kidney diseases, developing and commercializing therapies in nephrology. Portfolio includes Sibnayal for distal renal tubular acidosis (dRTA); licensed medications Likozam (clobazam) and Levidcen (levetiracetam) in France; and ADV7103, an experimental late-stage therapy for dRTA and cystinuria in children and adults.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Advicenne company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Synthego
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Synthego
2.2 - Growth funds investing in similar companies to Synthego
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Synthego
4.2 - Public trading comparable groups for Synthego
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →